Recent developments highlight Catalyst Crew Technologies' operational and strategic progress, including establishment of a Venezuelan telehealth subsidiary, capital structure updates, participation in industry events, and initial telehealth platform launch activities.

• Catalyst Crew Technologies established LataMed AI VE, C.A. to support Venezuelan telehealth operations [N6].
• The company provided a capital structure update regarding CEO equity restructuring initiatives [N7].
• Catalyst Crew Technologies announced plans to attend HLTH Europe 2026, indicating engagement with healthcare industry events [N8].
• The company announced the initial launch of its telehealth platform, marking a milestone in operational deployment [N6].

Catalyst Crew Technologies is developing a modular AI healthcare analytics platform targeting multiple clinical domains, including cardiovascular, pulmonary, and neurological applications, which could address unmet needs in Latin American healthcare markets. The company's technology-enabled healthcare services coordination model aims to optimize clinical workflows and patient management through telehealth and hybrid care delivery. Establishing operations through a Venezuelan subsidiary and securing intellectual property rights may position the company to capitalize on emerging digital health trends in the region. Recent organizational developments, including leadership appointments and participation in industry events, indicate progress in operational structuring and market engagement.

Catalyst Crew Technologies remains a development-stage company with no revenue and a history of net losses, raising substantial doubt about its ability to continue as a going concern. The company faces significant risks including dependence on additional financing, regulatory uncertainties in healthcare and AI sectors, potential challenges in intellectual property ownership, and operational risks associated with conducting business in Venezuela. The small management team and concentration of ownership in the CEO may limit governance and strategic flexibility. Competition from larger, established healthcare technology and AI companies may hinder the company's ability to commercialize its products and gain market acceptance.

Catalyst Crew Technologies' moat is currently limited due to its development-stage status and lack of commercialized products or revenue. The company holds proprietary intellectual property related to its AI healthcare analytics platform and services coordination model, which it acquired from its CEO and assigned to its Venezuelan subsidiary. While this IP forms the basis of its technology, the company acknowledges risks related to intellectual property ownership and protection. Its focus on Latin American healthcare markets, particularly Venezuela, may offer niche opportunities, but the company faces significant competition from established healthcare technology and AI firms with greater resources. The company's small management team and reliance on external financing further constrain its competitive position at this stage.

• Development Stage and Lack of Revenue: The company has not generated revenue from its current operations and remains in the development stage, with no assurance that its AI healthcare technologies will become commercially viable.
• Going Concern and Financing Risk: Catalyst Crew has limited financial resources, a working capital deficit, and relies on external financing. There is substantial doubt about its ability to continue as a going concern without additional capital.
• Regulatory and Compliance Risks: The company operates in a complex regulatory environment involving healthcare, telemedicine, data privacy, and AI regulations, which may require significant time and resources to navigate and could impact commercialization.
• Intellectual Property Risks: The company depends on intellectual property acquired from its CEO, with potential risks related to ownership challenges or the need for additional actions to protect or defend such rights.
• Geopolitical and Operational Risks in Venezuela: Operating through a Venezuelan subsidiary exposes the company to economic instability, currency controls, regulatory uncertainty, political developments, and potential limitations on repatriation of funds.
• Management and Governance Concentration: The CEO owns a majority of the company's stock and holds multiple executive roles, concentrating control and potentially limiting other shareholders' influence and succession planning.
• Competitive and Technological Risks: The healthcare AI industry is highly competitive and rapidly evolving, with risks that the company's technology may become obsolete or less competitive relative to established players with greater resources.

• Catalyst Crew Technologies Corp. is a development-stage technology company focused on AI-enabled healthcare technology solutions, specifically an AI healthcare analytics platform and a technology-enabled healthcare services coordination model [S1].
• The company transitioned its business focus in February 2026 following acquisition of healthcare technology assets and intellectual property from its CEO [S1].
• The AI healthcare platform under development includes modular, adaptable technologies intended to support cardiovascular (CardioAI), pulmonary (PulmoAI), and neurological (NeuroAI) clinical domains [S1].
• The company has not yet commercialized its technologies and has not generated revenue from current operations as of December 31, 2025 [S1].
• Operations are conducted through a wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., established in March 2026 to support Latin American strategy [S1].
• Certain intellectual property assets were assigned to the Venezuelan subsidiary in April 2026 as part of internal reorganization [S1].
• The company intends to focus on Latin American healthcare markets, initially Venezuela, with plans for phased geographic expansion subject to regulatory and infrastructure considerations [S1].
• The business model includes software licensing, digital platform access, and coordinated healthcare service infrastructure, with potential revenue from subscription licensing, usage-based fees, and telehealth service coordination [S1].
• The company has not yet entered into binding commercial agreements or generated revenue [S1].
• Regulatory compliance is a significant consideration, with healthcare, telemedicine, data privacy, and AI regulations potentially impacting development and commercialization [S1].
• The company had no full-time employees as of December 31, 2025, relying on independent contractors and expects to expand workforce as development progresses [S1].
• The company has a history of corporate reorganizations and was originally incorporated in 2008, with recent change in control in February 2026 when Dr. Kevin Rodan Levy acquired controlling interest and became CEO and sole director [S1].
• Financial snapshot as of March 31, 2026: total assets of $7.824 million (primarily intangible assets), current liabilities of $683,673, and stockholders' deficit of $7.14 million [S2].
• The company recorded a net loss of $52,813 for the three months ended March 31, 2026, compared to a net loss of $24,455 for the same period in 2025 [S2].
• Operating expenses increased to $43,384 for Q1 2026 from $15,967 in Q1 2025, driven by higher professional fees [S2].
• The company had zero current assets and a working capital deficit of $683,673 as of March 31, 2026, with no cash or cash equivalents reported [S2].
• The company relies on equity financings and shareholder loans to fund operations and has limited financial resources, raising substantial doubt about its ability to continue as a going concern [S1][S2].
• The CEO owns a majority of the outstanding common stock, exercising significant control over corporate decisions [S1].
• Recent news highlights include establishment of LataMed AI VE, C.A. to support Venezuelan telehealth operations, capital structure updates regarding CEO equity restructuring, and participation in HLTH Europe 2026 [N6][N7][N8].